SANUWAVE (SNWV)
Builds non-contact ultrasound systems and applicators for wound care.
SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript
SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript
Sanuwave Health Q2 Earnings Call Highlights
Sanuwave Health NASDAQ: SNWV reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, as lower UltraMIST system sales offset continued growth in the company's recurring applicator business.
Sanuwave Announces Q2 FY2026 Financial Results
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.
Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results
EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results.
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6 to $9.8 million, above the high end of the revised guidance range of $8.5 to $9.5 million provided in the Company's press release dated June 16, 2026.
Sanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year.
Sanuwave Health Q1 Earnings Call Highlights
Sanuwave Health NASDAQ: SNWV reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes.
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn. , May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results.
Sanuwave Health Inc. (SNWV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANUWAVE Health Inc (SNWV) Shares Fall 7.2% -- GF Value Says Still Overvalued
On April 10, 2026, SANUWAVE Health Inc (SNWV) shares fell 7.2% to a current price of $16.84. The stock has experienced significant volatility, trading within a
Head to Head Survey: Sanuwave Health (NASDAQ:SNWV) and INLIF (NASDAQ:INLF)
Sanuwave Health (NASDAQ: SNWV - Get Free Report) and INLIF (NASDAQ: INLF - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership. Insider and Institutional Ownership 42.5% of Sanuwave Health
SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 27, 2026, at 8:30 AM (ET) to present its Q4 and Full Year 2025 financial results.
SANUWAVE Health (OTCMKTS:SNWV) and Arch Therapeutics (OTCMKTS:ARTH) Critical Review
Profitability This table compares Arch Therapeutics and SANUWAVE Health's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Arch Therapeutics -8,257.70% N/A -730.22% SANUWAVE Health -1.33% -23.83% -20.60% Institutional and Insider Ownership 6.9% of Arch Therapeutics shares are held by institutional investors. Comparatively, 42.5% of SANUWAVE Health
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Head to Head Analysis: SANUWAVE Health (OTCMKTS:SNWV) & InfuSystem (NYSE:INFU)
InfuSystem (NYSE: INFU - Get Free Report) and SANUWAVE Health (OTCMKTS:SNWV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Analyst Ratings This is a breakdown of recent